Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials

Core Insights - Fenebrutinib successfully met primary goals in two late-stage trials for treating two different forms of multiple sclerosis [1] Group 1 - The trials demonstrated efficacy in both relapsing and progressive forms of multiple sclerosis [1] - The positive results may enhance the company's position in the competitive multiple sclerosis treatment market [1] - These findings could lead to potential regulatory approvals and market entry [1]